US drug developer Novavax Inc said on Tuesday it was doubling its potential COVID-19 vaccine manufacturing capacity to two billion doses annually
Union health minister Harsh Vardhan on Thursday said that COVID-19 vaccine may be available in India by first half of 2021
Astrazeneca also signed a deal with Serum Institute of India to manufacture Oxford COVID-19 vaccine (MINT_PRINT)
Serum Institute of India, the world's largest producer of vaccines, will begin the trial of Novavax COVID-19 vaccine in October, minister of state Ashwini Kumar Choubey informed the Lok Sabha on Friday.
US drug developer Novavax Inc said on Tuesday it was doubling its potential COVID-19 vaccine manufacturing capacity to two billion doses annually under an agreement with Serum Institute of India. As part of the expanded agreement, Serum Institute will also manufacture the antigen component of the vaccine.
In August, Novavax signed a deal with Pune-based Serum Institute, to produce a minimum of one billion doses of its vaccine candidate, when approved, for low- and middle-income countries and India.
Dubbed NVX‑CoV2373, Novavax's vaccine is currently in mid-stage trials. The early-stage study showed it produced high levels of antibodies against the novel coronavirus.
"The trill will be initiated in second half of October after the vaccine is manufactured by the Serum Institute," Choubey said in his written reply to Lok Sabha. The trial is led by Indian Council of Medical Research-National AIDS Research Institute (NARI), Pune, Choubey added.
Commenting on the deal, Stanley C. Erck, president and chief executive officer of Novavax, " The agreement with Serum Institute enhances Novavax’ commitment to equitable global delivery of our COVID-19 vaccine. With this arrangement, we have now put in place a global supply chain that includes the recently acquired Praha Vaccines and partnerships with leading biologics manufacturers, enabling production on three continents."
British-Swedish firm Astrazeneca also signed a deal with Serum Institute of India to manufacture the COVID-19 vaccine developed by the University of Oxford. The advanced stage clinical trial of Oxford COVID-19 vaccine is presently going on in the country.
Union health minister Harsh Vardhan on Thursday said that COVID-19 vaccine may be available in India by first half of 2021. "We are not lagging behind anyone else in the whole world in our efforts to contribute towards the vaccine against COVID... In India we have about 7-8 vaccine candidates, three of them in the clinical trial phases and rest in the pre- clinical trials," Vardhan said earlier.
Source - liveMint
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.